Consider combination antibiotic protocols for persistent infection

For chronic or persistent Eurasian borreliosis, some practitioners use combination antibiotic strategies targeting different bacterial forms: cell-wall active agents (amoxicillin, ceftriaxone) for replicating spirochetes, intracellular agents (azithromycin, hydroxychloroquine) for intracellular persistence, and anti-biofilm agents (tinidazole, metronidazole) for round-body/cyst forms. This approach is advocated by ILADS guidelines but not by IDSA.

Why It Works

Borrelia exists in multiple morphological forms: spirochetal (replicating), round-body/cyst (dormant), and biofilm. Each form has different antibiotic susceptibility. Combination therapy aims to target all forms simultaneously. Hydroxychloroquine raises intracellular pH, enhancing the activity of azithromycin against intracellular organisms.

Tips

• This approach is controversial; IDSA guidelines do not recommend prolonged or combination antibiotics beyond standard courses
• ILADS guidelines recommend individualized treatment durations based on clinical response
• Requires close medical supervision and monitoring for side effects (hepatic, cardiac QT prolongation with azithromycin/hydroxychloroquine)
• Discuss the evidence and guidelines with an infectious disease specialist experienced in both perspectives